nach oben

Erschienen in:

01.05.2011 | Laboratory Investigation - Human/Animal Tissue

Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids

verfasst von: Jesper Kolenda, Stine Skov Jensen, Charlotte Aaberg-Jessen, Karina Christensen, Claus Andersen, Nils Brünner, Bjarne Winther Kristensen

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Tumor hypoxia has been attributed to play a crucial role in tumorigenesis and therapeutic resistance. Recently, it has been suggested that hypoxia leads to and maintains the undifferentiated state of tumor stem cells, thereby contributing to chemoresistance. The aim of the present study is to investigate the influence of hypoxia on the protein expression of a panel of stem cell and chemoresistance markers using in vivo-like multicellular tumor spheroids derived from a glioblastoma short-term culture with tumor stem cell properties (SJ-1) as well as a conventional glioblastoma cell line (U87). Spheroids were formed in 21% and 1% O₂ in serum-free medium. The immunohistochemical panel included hypoxia (HIF-1α, HIF-2α), proliferation (Ki-67), and stem cell markers (CD133, podoplanin, Bmi-1, nestin, Sox-2) as well as markers related to chemoresistance (MGMT, TIMP-1, Lamp-1, MRP1, MDR-1). As spheroids derived in hypoxia were smaller than in normoxia, a set of experiments was included in which the culturing time of hypoxic spheroids was extended to obtain equally sized spheroids. The results showed that expression of HIF-1α and HIF-2α was increased in hypoxia, whereas Ki-67 was reduced. Expression of stem cell markers CD133, podoplanin, Bmi-1, and nestin was increased in hypoxia, whereas Sox-2 was increased in SJ-1 only. TIMP-1 and Lamp-1 were increased in both SJ-1 and U87. In conclusion, the tumor cell phenotype related to stemness, and thereby potentially to chemoresistance, seems to depend on the oxygen tension, suggesting that development of therapeutic strategies targeting tumor stem cells should take oxygen tension into account.

Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760. doi:10.1038/nature05236 PubMedCrossRef

Bredel M (2001) Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev 35:161–204. doi:10.1016/S0165-0173(01)00045-5 PubMedCrossRef

Höckel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266–276. doi:10.1093/jnci/93.4.266 PubMedCrossRef

Jensen RL (2006) Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures. Neurosurg Focus 20:E24. doi:10.3171/foc.2006.20.4.16 PubMedCrossRef

Johannessen TC, Bjerkvig R, Tysnes BB (2008) DNA repair and cancer stem-like cells—potential partners in glioma drug resistance? Cancer Treat Rev 34:558–567. doi:10.1016/j.ctrv.2008.03.125 PubMedCrossRef

Kang MK, Her BI, Ko MH, Kim CH, Cha SH, Kang SK (2008) Potential identity of multi-potential cancer stem-like subpopulation after radiation of cultured brain glioma. BMC Neurosci 9:15. doi:10.1186/1471-2202-9-15 PubMedCrossRef

Kang MK, Kang SK (2007) Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev 16:837–847. doi:10.1089/scd.2007.0006 PubMedCrossRef

Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH, Devi SN, Kaur B, Van Meir EG (2004) Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 64:920–927PubMedCrossRef

Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN (2009) The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8:3274–3284PubMedCrossRef

10.

Zhao D, Najbauer J, Garcia E, Metz MZ, Gutova M, Glackin CA, Kim SU, Aboody KS (2008) Neural stem cell tropism to glioma: critical role of tumor hypoxia. Mol Cancer Res 6:1819–1829. doi:10.1158/1541-7786.MCR-08-0146 PubMedCrossRef

11.

Csete M (2005) Oxygen in the cultivation of stem cells. Ann NY Acad Sci 1049:1–8. doi:10.1196/annals.1334.001 PubMedCrossRef

12.

Anelli V, Gault CR, Cheng AB, Obeid LM (2008) Sphingosine Kinase 1 is up-regulated during hypoxia in U87MG glioma cells: role of hypoxia-inducible factors 1 and 2. J Biol Chem 283:3365–3375. doi:10.1074/jbc.M708241200 PubMedCrossRef

13.

Benizri E, Ginouves A, Berra E (2008) The magic of the hypoxia-signaling cascade. Cell Mol Life Sci 65:1133–1149. doi:10.1007/s00018-008-7472-0 PubMedCrossRef

14.

Blazek ER, Foutch JL, Maki G (2007) Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133-cells, and the CD133 + sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 67:1–5. doi:10.1016/j.ijrobp.2006.09.037 PubMedCrossRef

15.

Diabira S, Morandi X (2008) Gliomagenesis and neural stem cells: key role of hypoxia and concept of tumor “neo-niche”. Med Hypotheses 70:96–104. doi:10.1016/j.mehy.2007.04.024 PubMedCrossRef

16.

Khaitan D, Chandna S, Arya MB, Dwarakanath BS (2006) Establishment and characterization of multicellular spheroids from a human glioma cell line; implications for tumor therapy. J Transl Med 4:12. doi:10.1186/1479-5876-4-12 PubMedCrossRef

17.

Platet N, Liu SY, Atifi ME, Oliver L, Vallette FM, Berger F, Wion D (2007) Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 258:286–290. doi:10.1016/j.canlet.2007.09.012 PubMedCrossRef

18.

Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828PubMed

19.

Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL (2000) Expression of hypoxia-inducible factor 1 alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88:2606–2618. doi:10.1002/1097-0142(20000601)88:11<2606:AID-CNCR25>3.0.CO;2-W PubMedCrossRef

20.

Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G (2000) Overexpression of hypoxia-inducible factor 1 alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60:4693–4696PubMed

21.

Daponte A, Ioannou M, Mylonis I, Simos G, Minas M, Messinis IE, Koukoulis G (2008) Prognostic significance of hypoxia-inducible Factor 1 alpha (HIF-1 alpha) expression in serous ovarian cancer: an immunohistochemical study. BMC Cancer 8:335. doi:10.1186/1471-2407-8-335 PubMedCrossRef

22.

Ke HL, Wei YC, Yang SF, Li CC, Wu DC, Huang CH, Wu WJ (2008) Overexpression of hypoxia-inducible factor-1 alpha predicts an unfavorable outcome in urothelial carcinoma of the upper urinary tract. Int J Urol 15:200–205. doi:10.1111/j.1442-2042.2007.01978.x PubMedCrossRef

23.

Soeda A, Park M, Lee D, Mintz A, ndroutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, Pollack IF, Park DM (2009) Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1 alpha. Oncogene 28:3949–3959. doi:10.1038/onc.2009.252 PubMedCrossRef

24.

Agata H, Kagami H, Watanabe N, Ueda M (2008) Effect of ischemic culture conditions on the survival and differentiation of porcine dental pulp-derived cells. Differentiation 76:981–993. doi:10.1111/j.1432-0436.2008.00282.x PubMed

25.

Gordan JD, Simon MC (2007) Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 17:71–77. doi:10.1016/j.gde.2006.12.006 PubMedCrossRef

26.

Günther W, Pawlak E, Damasceno R, Arnold H, Terzis AJ (2003) Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids. Br J Cancer 88:463–469. doi:10.1038/sj.bjc.6600711 PubMedCrossRef

27.

Kaaijk P, Troost D, Das PK, Leenstra S, Bosch DA (1995) Long-term culture of organotypic multicellular glioma spheroids: a good culture model for studying gliomas. Neuropathol Appl Neurobiol 21:386–391PubMedCrossRef

28.

Sutherland RM, Durand RE (1976) Radiation response of multicell spheroids–an in vitro tumour model. Curr Top Radiat Res Q 11:87–139PubMed

29.

Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK, Fine HA (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9:391–403. doi:10.1016/j.ccr.2006.03.030 PubMedCrossRef

30.

Beier D, Rohrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, Proescholdt M, Brawanski A, Bogdahn U, Trampe-Kieslich A, Giebel B, Wischhusen J, Reifenberger G, Hau P, Beier CP (2008) Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 68:5706–5715. doi:10.1038/nature05236 PubMedCrossRef

31.

Günther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, Modrusan Z, Meissner H, Westphal M, Lamszus K (2007) Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27:2897–2909. doi:10.1038/sj.onc.1210949 PubMedCrossRef

32.

Korur S, Huber RM, Sivasankaran B, Petrich M, Morin P Jr, Hemmings BA, Merlo A, Lino MM (2009) GSK3beta regulates differentiation and growth arrest in glioblastoma. PLoS ONE 4:e7443. doi:10.1371/journal.pone.0007443 PubMedCrossRef

33.

Pontén J, Macintyre EH (1968) Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand 74:465–486PubMedCrossRef

34.

Qiang L, Yang Y, Ma YJ, Chen FH, Zhang LB, Liu W, Qi Q, Lu N, Tao L, Wang XT, You QD, Guo QL (2009) Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett 279:13–21. doi:10.1016/j.canlet.2009.01.016 PubMedCrossRef

35.

Zhen Y, Zhao S, Li Q, Li Y, Kawamoto K (2010) Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas. Cancer Lett 292:64–72. doi:10.1016/j.canlet.2009.11.005 PubMedCrossRef

36.

Zhou ZH, Ping YF, Yu SC, Yi L, Yao XH, Chen JH, Cui YH, Bian XW (2009) A novel approach to the identification and enrichment of cancer stem cells from a cultured human glioma cell line. Cancer Lett 281:92–99. doi:10.1016/j.canlet.2009.02.033 PubMedCrossRef

37.

Favaro E, Nardo G, Persano L, Masiero M, Moserle L, Zamarchi R, Rossi E, Esposito G, Plebani M, Sattler U, Mann T, Mueller-Klieser W, Ciminale V, Amadori A, Indraccolo S (2008) Hypoxia inducible Factor-1{alpha} inactivation unveils a link between tumor cell metabolism and hypoxia-induced cell death. Am J Pathol 173:1186–1201. doi:10.2353/ajpath.2008.071183 PubMedCrossRef

38.

Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL, Dang CV (2001) Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem 276:7919–7926. doi:10.1074/jbc.M010189200 PubMedCrossRef

39.

Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS (2003) Hypoxia-inducible factor 1 alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol 23:359–369. doi:10.1128/MCB.23.1.359-369.2003 PubMedCrossRef

40.

Sutherland RM, Sordat B, Bamat J, Gabbert H, Bourrat B, Mueller-Klieser W (1986) Oxygenation and differentiation in multicellular spheroids of human colon carcinoma. Cancer Res 46:5320–5329PubMed

41.

Glicklis R, Merchuk JC, Cohen S (2004) Modeling mass transfer in hepatocyte spheroids via cell viability, spheroid size, and hepatocellular functions. Biotechnol Bioeng 86:672–680. doi:10.1002/bit.20086 PubMedCrossRef

42.

Singec I, Knoth R, Meyer RP, Maciaczyk J, Volk B, Nikkhah G, Frotscher M, Snyder EY (2006) Defining the actual sensitivity and specificity of the neurosphere assay in stem cell biology. Nat Methods 3:801–806. doi:10.1038/nmeth926 PubMedCrossRef

43.

McCord AM, Jamal M, Shankavaram UT, Lang FF, Camphausen K, Tofilon PJ (2009) Physiologic oxygen concentration enhances the stem-like properties of CD133 + human glioblastoma cells in vitro. Mol Cancer Res 7:489–497. doi:10.1158/1541-7786.MCR-08-0360 PubMedCrossRef

44.

Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC (1997) Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386:403–407. doi:10.1038/386403a0 PubMedCrossRef

45.

Holmquist-Mengelbier L, Fredlund E, Löfstedt T, Noguera R, Navarro S, Nilsson H, Pietras A, Vallon-Christersson J, Borg A, Gradin K, Poellinger L, Påhlman S (2006) Recruitment of HIF-1 alpha and HIF-2 alpha to common target genes is differentially regulated in neuroblastoma: HIF-2 alpha promotes an aggressive phenotype. Cancer Cell 10:413–423. doi:10.1016/j.ccr.2006.08.026 PubMedCrossRef

46.

Löfstedt T, Fredlund E, Holmquist-Mengelbier L, Pietras A, Ovenberger M, Poellinger L, Påhlman S (2007) Hypoxia inducible factor-2 alpha in cancer. Cell Cycle 6:919–926PubMedCrossRef

47.

Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D (1999) Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154:385–394PubMedCrossRef

48.

Ernst A, Hofmann S, Ahmadi R, Becker N, Korshunov A, Engel F, Hartmann C, Felsberg J, Sabel M, Peterziel H, Durchdewald M, Hess J, Barbus S, Campos B, Starzinski-Powitz A, Unterberg A, Reifenberger G, Lichter P, Herold-Mende C, Radlwimmer B (2009) Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res 15:6541–6550. doi:10.1158/1078-0432.CCR-09-0695 PubMedCrossRef

49.

Wicki A, Christofori G (2007) The potential role of podoplanin in tumour invasion. Br J Cancer 96:1–5. doi:10.1038/sj.bjc.6603518 PubMedCrossRef

50.

Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM, Van LM, Betticher DC (2001) The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 84:1372–1376. doi:10.1054/bjoc.2001.1791 PubMedCrossRef

51.

Glinsky GV, Berezovska O, Glinskii AB (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115:1503–1521. doi:10.1172/JCI23412 PubMedCrossRef

52.

Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL, Morrison SJ, Clarke MF (2003) Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423:302–305. doi:10.1038/nature01587 PubMedCrossRef

53.

Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, Bernier G (2009) BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci 29:8884–8896. doi:10.1523/JNEUROSCI.0968-09.2009 PubMedCrossRef

54.

Itahana K, Zou Y, Itahana Y, Martinez JL, Beausejour C, Jacobs JJ, Van LM, Band V, Campisi J, Dimri GP (2003) Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol 23:389–401. doi:10.1128/MCB.23.1.389-401.2003 PubMedCrossRef

55.

Schmitt CA (2003) Senescence, apoptosis and therapy–cutting the lifelines of cancer. Nat Rev Cancer 3:286–295. doi:10.1038/nrc1044 PubMedCrossRef

56.

Hockfield S, McKay RD (1985) Identification of major cell classes in the developing mammalian nervous system. J Neurosci 5:3310–3328PubMed

57.

Johansson CB, Momma S, Clarke DL, Risling M, Lendahl U, Frisen J (1999) Identification of a neural stem cell in the adult mammalian central nervous system. Cell 96:25–34. doi:10.1016/S0092-8674(00)80956-3 PubMedCrossRef

58.

Strojnik T, Røsland GV, Sakariassen PO, Kavalar R, Lah T (2007) Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol 68:133–143. doi:10.1016/j.surneu.2006.10.050 PubMedCrossRef

59.

Pistollato F, Chen HL, Schwartz PH, Basso G, Panchision DM (2007) Oxygen tension controls the expansion of human CNS precursors and the generation of astrocytes and oligodendrocytes. Mol Cell Neurosci 35:424–435. doi:10.1016/j.mcn.2007.04.003 PubMedCrossRef

60.

Schmitz M, Temme A, Senner V, Ebner R, Schwind S, Stevanovic S, Wehner R, Schackert G, Schackert HK, Fussel M, Bachmann M, Rieber EP, Weigle B (2007) Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer 96:1293–1301. doi:10.1038/sj.bjc.6603696 PubMedCrossRef

61.

Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 100:15178–15183. doi:10.1073/pnas.2036535100 PubMedCrossRef

62.

Nakagawa T, Ido K, Sakuma T, Takeuchi H, Sato K, Kubota T (2008) Prognostic significance of the immunohistochemical expression of O-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas. Neuropathology 84:31–37. doi:10.1111/j.1440-1789.2008.00983.x

63.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Triblot N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedCrossRef

64.

Nakagawa T, Kubota T, Ido K, Sakuma T, Matsuda K (2007) The combined effects of multiple chemotherapeutic agents for malignant glioma cells. J Neurooncol 84:31–37. doi:10.1007/s11060-007-9357-8 PubMedCrossRef

65.

Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K (1992) Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298:29–32. doi:10.1016/0014-5793(92)80015-9 PubMedCrossRef

66.

Yoshiji H, Harris SR, Raso E, Gomez DE, Lindsay CK, Shibuya M, Sinha CC, Thorgeirsson UP (1998) Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 75:81–87. doi:10.1002/(SICI)1097-0215(19980105)75:1<81:AID-IJC13>3.0.CO;2-G PubMedCrossRef

67.

Liu XW, Bernardo MM, Fridman R, Kim HR (2003) Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 278:40364–40372. doi:10.1074/jbc.M302999200 PubMedCrossRef

68.

Davidsen ML, Würtz SØ, Rømer MU, Sørensen NM, Johansen SK, Christensen IJ, Larsen JK, Offenberg H, Brünner N, Lademann U (2006) TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer 95:1114–1120. doi:10.1038/sj.bjc.6603378 PubMedCrossRef

69.

Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen HT, Brünner N, Foekens JA (2006) Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res 12:7054–7058. doi:10.1158/1078-0432.CCR-06-0950 PubMedCrossRef

70.

Sørensen NM, Byström P, Christensen IJ, Berglund A, Nielsen HJ, Brünner N, Glimelius B (2007) TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res 13:4117–4122. doi:10.1158/1078-0432.CCR-07-0186 PubMedCrossRef

71.

Aaberg-Jessen C, Christensen K, Offenberg H, Bartels A, Dreehsen T, Hansen S, Schrøder HD, Brünner N, Kristensen BW (2009) Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. J Neurooncol 95:117–128. doi:10.1007/s11060-009-9910-8 PubMedCrossRef

72.

Duffy MJ, McGowan PM, Gallagher WM (2008) Cancer invasion and metastasis: changing views. J Pathol 214:283–293. doi:10.1002/path.2282 PubMedCrossRef

73.

Lambert E, Boudot C, Kadri Z, Soula-Rothhut M, Sowa ML, Mayeux P, Hornebeck W, Haye B, Petitfrere E (2003) Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival. Biochem J 372:767–774. doi:10.1042/BJ20030187 PubMedCrossRef

74.

Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO, Bruserud O (2009) Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. Eur J Haematol 84(3):239–251. doi:10.1111/j.1600-0609.2009.01382.x PubMedCrossRef

75.

Glunde K, Guggino SE, Solaiyappan M, Pathak AP, Ichikawa Y, Bhujwalla ZM (2003) Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia 5:533–545PubMed

76.

Chen JW, Madamanchi N, Madamanchi NR, Trier TT, Keherly MJ (2001) Lamp-1 is upregulated in human glioblastoma cell lines induced to undergo apoptosis. J Biomed Sci 8:365–374. doi:10.1159/000054056 PubMedCrossRef

77.

Castino R, Demoz M, Isidoro C (2003) Destination ‘lysosome’: a target organelle for tumour cell killing? J Mol Recognit 16:337–348. doi:10.1002/jmr.643 PubMedCrossRef

78.

Kroemer G, Jäättelä M (2005) Lysosomes and autophagy in cell death control. Nat Rev Cancer 5:886–897. doi:10.1038/nrc1738 PubMedCrossRef

79.

Quintanilla-Dieck MJ, Codriansky K, Keady M, Bhawan J, Runger TM (2008) Cathepsin K in melanoma invasion. J Invest Dermatol 128:2281–2288. doi:10.1038/jid.2008.63 PubMedCrossRef

80.

Tu C, Ortega-Cava CF, Chen G, Fernandes ND, Cavallo-Medved D, Sloane BF, Band V, Band H (2008) Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts. Cancer Res 68:9147–9156. doi:10.1158/0008-5472.CAN-07-5127 PubMedCrossRef

81.

Liang BC (1996) Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J Neurooncol 29:149–155. doi:10.1007/BF00182138 PubMedCrossRef

82.

Reynolds BA, Weiss S (1992) Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255:1707–1710. doi:10.1126/science.1553558 PubMedCrossRef

83.

Tropepe V, Sibilia M, Ciruna BG, Rossant J, Wagner EF, van der Kooy D (1999) Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon. Dev Biol 208:166–188. doi:10.1006/dbio.1998.9192 PubMedCrossRef

84.

Kristensen BW, Noraberg J, Jakobsen B, Gramsbergen JB, Ebert B, Zimmer J (1999) Excitotoxic effects of non-NMDA receptor agonists in organotypic corticostriatal slice cultures. Brain Res 841:143–159. doi:10.1016/S0006-8993(99)01833-8 PubMedCrossRef

85.

Huhn SL, Mohapatra G, Bollen A, Lamborn K, Prados MD, Feuerstein BG (1999) Chromosomal abnormalities in glioblastoma multiforme by comparative genomic hybridization: correlation with radiation treatment outcome. Clin Cancer Res 5:1435–1443PubMed

86.

Sørensen IV, Fenger C, Winther H, Foged NT, Lademann U, Brünner N, Usher PA (2006) Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem 54:1075–1086. doi:10.1369/jhc.5A6896.2006 PubMedCrossRef

87.

Abramoff MD, Magelhaes PJ, Ram SJ (2004) Image processing with ImageJ. Biophotonics Int 11:36–42

Titel: Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids
verfasst von: Jesper Kolenda
Stine Skov Jensen
Charlotte Aaberg-Jessen
Karina Christensen
Claus Andersen
Nils Brünner
Bjarne Winther Kristensen
Publikationsdatum: 01.05.2011
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 1/2011
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-010-0357-8

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

A case of soft tissue metastasis from glioblastoma and review of the literature

Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors

Health-related quality of life and cognitive functioning in adult patients with supratentorial WHO grade II glioma: status prior to therapy

Which therapy works better in choroid plexus carcinomas?

Factors impacting volumetric white matter changes following whole brain radiation therapy